JP2023516745A5 - - Google Patents
Info
- Publication number
- JP2023516745A5 JP2023516745A5 JP2022553181A JP2022553181A JP2023516745A5 JP 2023516745 A5 JP2023516745 A5 JP 2023516745A5 JP 2022553181 A JP2022553181 A JP 2022553181A JP 2022553181 A JP2022553181 A JP 2022553181A JP 2023516745 A5 JP2023516745 A5 JP 2023516745A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- approximately
- pharmaceutical composition
- administered
- lsd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986541P | 2020-03-06 | 2020-03-06 | |
| US62/986,541 | 2020-03-06 | ||
| PCT/US2021/021101 WO2021178807A1 (en) | 2020-03-06 | 2021-03-05 | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023516745A JP2023516745A (ja) | 2023-04-20 |
| JP2023516745A5 true JP2023516745A5 (enExample) | 2024-03-06 |
Family
ID=77614361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022553181A Pending JP2023516745A (ja) | 2020-03-06 | 2021-03-05 | 小細胞肺癌および／または扁平上皮非小細胞肺癌の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230089536A1 (enExample) |
| EP (1) | EP4114398A1 (enExample) |
| JP (1) | JP2023516745A (enExample) |
| KR (1) | KR20220151637A (enExample) |
| CN (1) | CN115484958A (enExample) |
| AU (1) | AU2021230575A1 (enExample) |
| BR (1) | BR112022017637A2 (enExample) |
| CA (1) | CA3170456A1 (enExample) |
| IL (1) | IL296564A (enExample) |
| MX (1) | MX2022010912A (enExample) |
| WO (1) | WO2021178807A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276611B2 (en) | 2017-05-31 | 2022-01-06 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2021095835A1 (en) | 2019-11-13 | 2021-05-20 | Taiho Pharmaceutical Co., Ltd. | Novel salt of terphenyl compound |
| US20250049757A1 (en) * | 2021-09-30 | 2025-02-13 | Taiho Pharmaceutical Co. Ltd. | Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102400920B1 (ko) * | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| HUE068868T2 (hu) | 2015-07-30 | 2025-02-28 | Macrogenics Inc | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2019075327A1 (en) * | 2017-10-12 | 2019-04-18 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF MERKEL CELL CARCINOMA |
| WO2019083971A1 (en) * | 2017-10-23 | 2019-05-02 | Children's Medical Center Corporation | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY |
| AU2018377852B2 (en) * | 2017-11-29 | 2022-03-24 | Epiaxis Therapeutics Pty Ltd | Enhancing T-cell function and treating a T-cell dysfunctional disorder with a combination of an LSD inhibitor and a PD1 binding antagonist |
| MX2021015447A (es) * | 2019-06-13 | 2022-04-06 | Celgene Corp | Métodos de tratamiento del cáncer dirigidos a tumores fríos. |
-
2021
- 2021-03-05 EP EP21714748.7A patent/EP4114398A1/en not_active Withdrawn
- 2021-03-05 MX MX2022010912A patent/MX2022010912A/es unknown
- 2021-03-05 CN CN202180030907.0A patent/CN115484958A/zh active Pending
- 2021-03-05 IL IL296564A patent/IL296564A/en unknown
- 2021-03-05 KR KR1020227034176A patent/KR20220151637A/ko active Pending
- 2021-03-05 WO PCT/US2021/021101 patent/WO2021178807A1/en not_active Ceased
- 2021-03-05 AU AU2021230575A patent/AU2021230575A1/en not_active Abandoned
- 2021-03-05 BR BR112022017637A patent/BR112022017637A2/pt not_active Application Discontinuation
- 2021-03-05 CA CA3170456A patent/CA3170456A1/en active Pending
- 2021-03-05 US US17/909,292 patent/US20230089536A1/en not_active Abandoned
- 2021-03-05 JP JP2022553181A patent/JP2023516745A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023516745A5 (enExample) | ||
| Dangi et al. | Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody | |
| Petrone et al. | In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy | |
| Farroni et al. | Kinetics of the B-and T-cell immune responses after 6 months from SARS-CoV-2 mRNA vaccination in patients with rheumatoid arthritis | |
| Icenogle | COVID-19: infection or autoimmunity | |
| JP2022536412A5 (enExample) | ||
| Woolsey et al. | Immune correlates of postexposure vaccine protection against Marburg virus | |
| Miyazaki et al. | Corneal endothelial cells activate innate and acquired arm of anti-viral responses after cytomegalovirus infection | |
| Eggenhuizen et al. | Heterologous immunity between SARS-CoV-2 and pathogenic bacteria | |
| Luka et al. | Molecular characterization of peste des petits ruminants virus from the Karamoja region of Uganda (2007-2008) | |
| Aloisi et al. | MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis | |
| US20220257657A1 (en) | Manipulation and use of antigen-specific regulatory t cells | |
| An et al. | Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients | |
| Massilamany et al. | SJL mice infected with Acanthamoeba castellanii develop central nervous system autoimmunity through the generation of cross-reactive T cells for myelin antigens | |
| Lotonin et al. | Correlates of protection against African swine fever virus identified by a systems immunology approach | |
| CA3170456A1 (en) | Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc | |
| Calugareanu et al. | Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus. | |
| JP2024539370A5 (enExample) | ||
| Basem et al. | Detection of Epstein-Barr virus among chronic kidney disease patients in Najaf, Iraq | |
| US20250147046A1 (en) | New method for identifying herv-derived epitopes | |
| Dabbagh et al. | Behcet’s disease: from heat shock proteins to infections | |
| Nogimori et al. | mRNA vaccine induces cytotoxic CD8+ T-cell cross-reactivity against SARS-CoV-2 Omicron variant and regulates COVID-19 severity | |
| Bellanger et al. | Fungal peptides from pneumonitis hypersensitivity etiologic agents are able to induce specific cellular immune response | |
| US20260036592A1 (en) | DETECTION OF ANTI-VIRAL CDR3s IN CANCER | |
| Bartholomeus et al. | Transcriptomic profiling of different responder types in adults after a Priorix® vaccination |